Comprehensive molecular profiling in MOTION study

Olesya A Kuznetsova; Maxim V Ivanov; Alexandra A Lebedeva; Alexey A Tryakin; Egor M Veselovsky; Maria S Cheporova; Fedor V Moiseenko; Margarita S Gileva; Alena I Cherentsova; Anna N Tiatiushkina; Mikhail Y Fedyanin

doi:10.1016/j.cancergen.2025.06.001

Comprehensive molecular profiling in MOTION study

Cancer Genet. 2025 Jun 10:296-297:45-52. doi: 10.1016/j.cancergen.2025.06.001. Online ahead of print.

Affiliations

¹ Department of Chemotherapy, Federal State Budgetary Institution (N.N. Blokhin National Medical Research Center of Oncology) of the Ministry of Health of the Russian Federation, Moscow 115478, Russia; OncoAtlas LCC, Moscow 119049, Russia.
² OncoAtlas LCC, Moscow 119049, Russia; Sechenov First Moscow State Medical University, Moscow 119146, Russia.
³ OncoAtlas LCC, Moscow 119049, Russia.
⁴ Department of Chemotherapy, Federal State Budgetary Institution (N.N. Blokhin National Medical Research Center of Oncology) of the Ministry of Health of the Russian Federation, Moscow 115478, Russia.
⁵ Federal State Budgetary Educational Institution of higher education "Russian University of Medicine" of the Ministry of Health of the Russian Federation, Moscow 127994, Russia. Electronic address: masha.cheporova@mail.ru.
⁶ N.P. Napalkov St. Petersburg City Cancer Center, Saint Petersburg 197758, Russia.
⁷ Department of Chemotherapy, Federal State Budgetary Institution (N.N. Blokhin National Medical Research Center of Oncology) of the Ministry of Health of the Russian Federation, Moscow 115478, Russia; The Multidisciplinary Clinical Center Kommunarka, Moscow 108814, Russia.

PMID: 40532431
DOI: 10.1016/j.cancergen.2025.06.001

Abstract

Introduction: Comprehensive molecular profiling (CMP) and molecularly matched therapy (MMT) have uncertain roles in advanced solid tumors. This study evaluates CMP's real-world application in Russia.

Methods: A retrospective, multicenter study analyzed CMP data from 448 patients with advanced non-hematologic malignancies (2018-2024). Genomic alterations (GA) were classified by ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Results: ESCAT tiers included I (15.4 %), II (4.9 %), III (31.5 %), IV (19.6 %), and V/X (28.6 %). Therapy data were available for 374 patients. MMT was recommended for 56.9 % but implemented in only 23.2 % (MMT group, n = 87). MMT group showed better objective response rate (61.3 % vs. 37.1 %, p = 0.001), disease control rate (24.0 % vs. 9.2 %, p = 0.003), and progression-free survival ratio (PFS 2/1) ≥ 1.3 (45.0 % vs. 16.2 %, p < 0.01) compared to non-MMT group (n = 287). Median overall survival (OS) was borderline improved (12 vs. 8 months, HR 0.74, p = 0.06). Reasons for non-MMT management were low GA targetability (40 %), drug unavailability (30 %), clinical decline (23 %), and clinician preference (7 %). Patients with ≤3 prior therapies, ECOG performance status 0-1, and molecular tumor board discussion saw significant OS gains with MMT even for ESCAT III-V GA (5 vs. 18 months, HR 0.25, p < 0.01).

Conclusion: MMT following CMP offers clinical benefit for selected patients, even with ESCAT III-V GA, underscoring its potential in personalized oncology.

Keywords: Comprehensive molecular profiling; Genes alterations; Personalized oncology; Solid tumors.